Kairos Pharma Ltd. (NYSE American: KAPA) has announced a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer’s XOFIGO® (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) involving bone. The partnership aims to address the significant challenge of drug resistance in advanced prostate cancer, a disease that remains difficult to treat despite available therapies.
ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance. It is currently being evaluated in Phase 1 and Phase 2 clinical trials. In interim Phase 2 data, the company reported a median progression-free survival of more than 13 months in prostate cancer patients. XOFIGO, an alpha-emitting radiopharmaceutical, is the only FDA-approved treatment for symptomatic bone metastases in mCRPC patients.
The collaboration will investigate whether ENV-105 can enhance and extend responses to XOFIGO by targeting CD105, a protein associated with treatment resistance following androgen receptor inhibition and radiation therapy. Preclinical studies have demonstrated ENV-105’s ability to re-sensitize tumors to radiation, suggesting that combining the therapy with XOFIGO could provide a more durable treatment option for patients with advanced prostate cancer.
This partnership is significant because it combines two innovative approaches—an immunotherapeutic antibody and a targeted radiopharmaceutical—to potentially overcome resistance mechanisms that limit the efficacy of current treatments. If successful, the combination could offer new hope for patients with mCRPC, a condition with limited therapeutic options and poor prognosis.
Kairos Pharma, based in Los Angeles, is focused on oncology therapeutics using structural biology to address drug resistance and immune suppression. The company’s lead candidate, ENV-105, targets CD105, a key driver of resistance and relapse in response to standard therapies. ENV-105 is in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. As of the date of this press release, ENV-105 has not been approved as safe or effective by the FDA or any other regulatory body.
For more information, visit the press release at https://ibn.fm/emSc4 and the company’s newsroom at https://ibn.fm/KAPA.
